Mesa Laboratories, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59064R1095
USD
77.15
1.09 (1.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Mesa Laboratories, Inc. stock-summary
stock-summary
Mesa Laboratories, Inc.
Pharmaceuticals & Biotechnology
Mesa Laboratories, Inc. designs, manufacturers and markets quality control products and services. It operates through four segments: Sterilization and Disinfection Control, Instrument Division, Cold Chain Monitoring Division and Cold Chain Packaging Division. Its Sterilization and Disinfection Control Division provides testing services, along with the manufacture and marketing of biological, chemical and cleaning indicators. Its Instruments Division designs, manufactures and markets quality control instruments and disposable products. Its Cold Chain Monitoring Division designs, develops and markets systems, which are used to monitor various environmental parameters. Its Cold Chain Packaging Division provides thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport. It also provides immunoassay and peptide synthesis instrument solutions to discover, develop and manufacture biotherapeutics.
Company Coordinates stock-summary
Company Details
12100 W 6th Ave , LAKEWOOD CO : 80228-1252
stock-summary
Tel: 1 303 9878000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 57 Schemes (51.06%)

Foreign Institutions

Held by 81 Foreign Institutions (8.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. John Sullivan
Chairman of the Board
Mr. Gary Owens
President, Chief Executive Officer, Director
Ms. Shannon Hall
Director
Ms. Jennifer Alltoft
Independent Director
Mr. Evan Guillemin
Independent Director
Mr. David Kelly
Independent Director
Mr. John Schmieder
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
60 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 351 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.95

stock-summary
Return on Equity

-0.36%

stock-summary
Price to Book

2.03